media – Page 633 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Amgen Ventures Invests in GNS Healthcare to Advance Applications of its REFS™ Causal Machine Learning and Simulation AI Platforms

GNS Healthcare (GNS), a leading precision medicine company, today announced that it has raised an additional $6 million in equity from Amgen Ventures with participation from existing investor Alexandria Real Estate Equities. The funds will be used to further develop the company's REFS™ causal machine learning and simulation platform and solutions across drug discovery & development, value-based drug solutions, care management, and health system business optimization. With this investment, Amgen Ventures joins other leading biopharma companies Celgene and Zambon Pharmaceuticals, leading health plans Regence Blue Cross Blue Shield (Cambia Health Solutions), and Horizon Blue Cross of NJ and provider Heritage Provider Network, in addition to Mitsui, GHO Capital, and Fort Rock Capital as shareholders of GNS.
- Source: Prnewswire
- 571
- September 5, 2017
Market Views platform solution
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Gazyva® (obinutuzumab) in combination with chemotherapy followed by Gazyva alone for people with previously untreated follicular lymphoma, one of the most common blood cancers among adults. Follicular lymphoma, a slow-growing (indolent) form of non-Hodgkin’s lymphoma, is incurable and characterized by cycles of remission and relapse.
- Source: biospace
- 564
- September 5, 2017
cancer FDA follicular lymphoma New Approvals sBLA
Apollo Endosurgery gets CE-Mark for managed weight loss system

Apollo Endosurgery has received CE-Mark for its ORBERA365 Managed Weight Loss System allowing commercialisation in the European Union (EU) and member countries of the European Economic Area.
- Source: medicaldevice-network
- 886
- September 4, 2017
CE EU New Approvals weight loss
Hologic introduces new Brevera breast biopsy system

Medical technology firm Hologic has introduced new Brevera breast biopsy system with CorLumina imaging technology in the US.
- Source: diagnosticimaging.medicaldevices-business-review
- 502
- September 4, 2017
breast biopsy Company Insight
LabCorp completes $1.2B Chiltern buy

Diagnostics company LabCorp (NYSE:LH) said today that it has closed its $1.2 billion acquisition of contract research organization Chiltern International.
- Source: drugdeliverybusiness
- 667
- September 4, 2017
acquisition Clinical Market Views oncology
2nd International Conference on Pediatric Neurology

Pediatric Neurology 2017 will focus on the latest and exodus innovations in all areas of Pediatric neurology research which offers exclusive opportunity for investigators across the globe to meet, network, and perceive new scientific innovations. This year's annual congress highlights the theme, "Channelizing the novel ideas for treating Pediatric Neurological Disorders" which reflects the innovative progress in Pediatric Neurology research.
- Source: drugs
- 596
- September 1, 2017
Exhibitions & Activities Pediatric Neurology
Stent Tek Closes Series A Investment Round for its ePATH AVF Device, Aiming to Improve Vascular Access for Hemodialysis

Stent Tek, a medical device company that is developing a minimally invasive catheter system for dialysis patients, announced today it has successfully closed a Series A funding round with investments from two institutional investors.
- Source: infomeddnews
- 406
- September 1, 2017
dialysis Market Views Stent Tek
FDA approves Teva’s Austedo for tardive dyskinesia

Teva’s Austedo is now the first and only therapy approved in the US to treat both tardive dyskinesia and chorea associated with Huntington’s disease.
- Source: news.open-medical
- 661
- September 1, 2017
chorea FDA New Approvals tardive dyskinesia Teva
Nemaura develops medical grade diabetes management app

Nemaura Medical Inc. (NMRD), a medical technology company focused on the development and commercialization of sugarBEAT®, a wireless adhesive skin-patch for adjunctive use by diabetics as a non-invasive and needle-free continuous glucose monitoring (CGM) system announced today that it has completed development of a medical grade app prepared and verified in accordance with ISO13485 quality systems and the appropriate medical devices directives, and designed to be used with the sugarBEAT® device or with glucose meters and strips to display glucose levels on users android mobile devices.
- Source: Drugdeliverybusiness
- 664
- September 1, 2017
diabetes glucose Nemaura Medical Researches
Why do you always lose clients?

The vexing problem of how to increase the loyalty of clients has always been troublesome to people specializing in foreign trade. Salesmen often find that their clients may say goodbye to them and end their business relationship, simply to start a new one and on other occasions, their clients disappear without any notice. In order to mitigate issues such as these, we should know what causes this behavior and how to remedy the problem.
- Source: Ddu
- 2,207
- September 1, 2017
client Ddu College quality

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.